These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39046277)

  • 21. Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir.
    Shiraki K; Tan L; Daikoku T; Takemoto M; Sato N; Yoshida Y
    Antiviral Res; 2020 Aug; 180():104829. PubMed ID: 32569704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 3, randomized, double-blind, placebo-controlled study evaluating a single, patient-initiated dose of amenamevir for recurrent herpes labialis.
    Kawashima M; Watanabe D; Fujio K; Komazaki H
    J Dermatol; 2023 Mar; 50(3):311-318. PubMed ID: 36353762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Herpes zoster guideline of the German Dermatology Society (DDG).
    Gross G; Schöfer H; Wassilew S; Friese K; Timm A; Guthoff R; Pau HW; Malin JP; Wutzler P; Doerr HW
    J Clin Virol; 2003 Apr; 26(3):277-89; discussion 291-3. PubMed ID: 12637076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial.
    Wutzler P; De Clercq E; Wutke K; Färber I
    J Med Virol; 1995 Jul; 46(3):252-7. PubMed ID: 7561799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression.
    Leuvenink R; Aeschlimann F; Baer W; Berthet G; Cannizzaro E; Hofer M; Kaiser D; Schroeder S; Heininger U; Woerner A
    Pediatr Rheumatol Online J; 2016 Jun; 14(1):34. PubMed ID: 27256096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial.
    Shafran SD; Tyring SK; Ashton R; Decroix J; Forszpaniak C; Wade A; Paulet C; Candaele D
    J Clin Virol; 2004 Apr; 29(4):248-53. PubMed ID: 15018852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients.
    Tyring S; Belanger R; Bezwoda W; Ljungman P; Boon R; Saltzman RL;
    Cancer Invest; 2001; 19(1):13-22. PubMed ID: 11291551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes.
    Takada A; Katashima M; Kaibara A; Sawamoto T; Zhang W; Keirns J
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):365-70. PubMed ID: 27129009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults.
    Beutner KR; Friedman DJ; Forszpaniak C; Andersen PL; Wood MJ
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1546-53. PubMed ID: 7492102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-benefit of oral acyclovir in the treatment of herpes zoster.
    Kubeyinje EP
    Int J Dermatol; 1997 Jun; 36(6):457-9. PubMed ID: 9248895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults.
    Pott Junior H; de Oliveira MFB; Gambero S; Amazonas RB
    Int J Infect Dis; 2018 Jul; 72():11-15. PubMed ID: 29746903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of acyclovir-resistant herpes zoster infection by amenamevir.
    Onaka T; Shiraki K; Yonezawa A
    J Dermatol; 2021 Sep; 48(9):e478-e479. PubMed ID: 34137062
    [No Abstract]   [Full Text] [Related]  

  • 33. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial.
    Tyring SK; Plunkett S; Scribner AR; Broker RE; Herrod JN; Handke LT; Wise JM; Martin PA;
    J Med Virol; 2012 Aug; 84(8):1224-32. PubMed ID: 22711350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral antivirals revisited in the treatment of herpes zoster: what do they accomplish?
    Nikkels AF; Piérard GE
    Am J Clin Dermatol; 2002; 3(9):591-8. PubMed ID: 12444801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
    López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
    Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Varicella-Zoster Meningitis and Myelitis After Herpes Zoster Dermatitis Treatment With Amenamevir: A Case Series and Literature Review.
    Tada S; Kaito Y; Watanabe A; Sugiyama Y; Nishigaichi A; Miwa T; Watanabe K; Hazama T; Takahashi D
    Cureus; 2024 Feb; 16(2):e54775. PubMed ID: 38524092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral therapy for varicella and herpes zoster.
    Arvin AM
    Semin Pediatr Infect Dis; 2002 Jan; 13(1):12-21. PubMed ID: 12118839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment.
    Shiraki K; Takemoto M; Daikoku T
    Expert Rev Anti Infect Ther; 2021 Nov; 19(11):1415-1425. PubMed ID: 33853490
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunocompromised patients, herpes zoster and acyclovir.
    Elder M; Thomas MG; Ellis-Pegler RB
    N Z Med J; 1996 May; 109(1022):196. PubMed ID: 8657394
    [No Abstract]   [Full Text] [Related]  

  • 40. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.
    Whitley RJ; Weiss H; Gnann JW; Tyring S; Mertz GJ; Pappas PG; Schleupner CJ; Hayden F; Wolf J; Soong SJ
    Ann Intern Med; 1996 Sep; 125(5):376-83. PubMed ID: 8702088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.